Cargando…
Sphenopalatine ganglion block for refractory COVID-19 headache: a descriptive case series
Coronavirus SARS-CoV-2 is responsible for the COVID-19 pandemic, and headache is reported in 6.5% to 34% of all cases. There is little published evidence on the pharmacological treatment of COVID-19 headache. This case series presents six COVID-19 infected patients with refractory headache in which...
Autores principales: | Machado, Felipe Chiodini, Carone Neto, Gilson, Carone, Rebeca Santiago Duarte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080502/ https://www.ncbi.nlm.nih.gov/pubmed/33932392 http://dx.doi.org/10.1016/j.bjane.2021.04.024 |
Ejemplares similares
-
Sphenopalatine Ganglion Block for the Treatment of Acute Migraine Headache
por: Binfalah, Mohamed, et al.
Publicado: (2018) -
Sphenopalatine ganglion block for abortive treatment of a migraine headache
por: Berger, Amnon A., et al.
Publicado: (2020) -
The Efficacy of Sphenopalatine Ganglion Block and Radiofrequency Denervation in the Treatment of Cluster Headache: A Case Series
por: Amighi, Dorsa, et al.
Publicado: (2020) -
Intranasal lignocaine spray for sphenopalatine ganglion block for postdural puncture headache
por: Dubey, Preksha, et al.
Publicado: (2018) -
Use of the Sphenopalatine Ganglion Block to Treat Migraine Headaches in the Emergency Department
por: Morgan, Aaron, et al.
Publicado: (2022)